Lixte Biotechnology Holdings Inc
Company Profile
Business description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Contact
680 East Colorado Boulevard
Suite 180
PasadenaCA91101
USAT: +1 631 830-7092
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.50 | 23.70 | -0.27% |
| CAC 40 | 8,086.05 | 20.11 | -0.25% |
| DAX 40 | 23,960.59 | 116.28 | -0.48% |
| Dow JONES (US) | 47,885.97 | 228.29 | -0.47% |
| FTSE 100 | 9,774.32 | 89.53 | 0.92% |
| HKSE | 25,366.47 | 102.31 | -0.40% |
| NASDAQ | 22,693.32 | 418.14 | -1.81% |
| Nikkei 225 | 48,916.94 | 595.34 | -1.20% |
| NZX 50 Index | 13,251.57 | 44.34 | -0.33% |
| S&P 500 | 6,721.43 | 78.83 | -1.16% |
| S&P/ASX 200 | 8,564.60 | 20.60 | -0.24% |
| SSE Composite Index | 3,876.40 | 6.12 | 0.16% |